CTP utilization data reveals how cellular and tissue-based products are actually applied across care settings, and that picture differs meaningfully from claims volume or sales figures alone. A Q-code showing up on a Medicare Part B claim tells you a product was billed and how many square centimeters were billed for it. It does not tell you how large the wound was, what share of it the graft covered, whether the application contributed to closure, or how that product performed relative to alternatives used earlier in the same episode. For manufacturers supporting post-market evidence commitments, payers evaluating coverage policy, and investors sizing a product’s real footprint, that gap matters. This article breaks down where CTP utilization data comes from, what each source can and cannot tell you, and how to avoid the interpretation errors that make national claims totals look like market share when they aren’t.
Most publicly cited CTP utilization figures trace back to Medicare Part B or carrier-level claims data, built on HCPCS Q-codes submitted for reimbursement. This data has real strengths: it is standardized, auditable, and covers a large share of the Medicare fee-for-service population being treated for DFUs, VLUs, and other chronic wounds. But claims data records a billing event, not a clinical one. Nearly every skin substitute Q-code is defined per square centimeter, so the unit count does carry one real measurement — how much product was billed. That is the only clinical dimension it carries. It says nothing about wound size or duration, comorbidities, prior therapy, application technique, or outcome. Two providers billing the same Q-code and the same unit count can be treating patients whose wounds, risk profiles, and probability of healing have almost nothing in common.
Registry and EHR-derived data work differently. Platforms built on direct wound center documentation, such as Intellicure Analytics’ Wound Care Industry Dashboard, capture utilization at the point of care: which product was applied, to which wound type, in what setting, and what happened at the next visit. This is granular in ways claims data structurally cannot be, because it originates from the clinical record rather than the reimbursement transaction.
The two sources also move on different clocks. Medicare claims reach analysts well behind real-world activity: quarterly research files arrive roughly four to five months after a quarter closes at about 93% claims maturity, and final-action annual files are generally not distributed until about 14 months after year end. Commercial aggregators compress that somewhat but still work from adjudicated data. Either way, a claims-based read on a recently launched product is describing the past, not the present. Registry and EHR data pulled from active wound center workflows can reflect utilization patterns close to real time, which matters when a manufacturer needs to know how a product is being adopted this quarter, not what happened last year. Analysts who treat either source as a full national census will overstate their own precision — a limitation this article returns to below.
How Does CTP Use Differ Across Care Settings?
Product mix and application frequency are not uniform across the settings where CTPs get used. Hospital-based outpatient wound centers, skilled nursing facilities, and home health agencies operate under different payment mechanics, different coverage rules, and different clinician specialization, and all three shape which products actually reach the wound. The payment differences are structural rather than subtle: CTP application in a hospital outpatient department is billed to Part B, while a graft applied during a covered Part A SNF stay or inside a home health episode falls under a bundled payment rather than being separately payable. Coverage rules, meanwhile, vary by MAC jurisdiction rather than by setting — and since the MACs withdrew their unified DFU and VLU skin substitute LCDs in late December 2025, only Novitas, First Coast, and CGS have an active skin substitute coverage policy at all. In the remaining jurisdictions, coverage is decided case by case against the reasonable-and-necessary standard.
Hospital-based wound centers generally see higher-acuity DFU and VLU presentations and tend to run more frequent CTP application cycles, often under the supervision of physicians and advanced practice clinicians with dedicated wound care training. SNFs and home health settings work under different constraints: episode length, staffing continuity, and the practical logistics of storing and applying temperature-sensitive products all affect which CTPs get selected and how consistently they get reapplied on schedule. A product with strong outcomes data from hospital-based center studies is not automatically appearing with the same frequency in a home health context, and utilization data that doesn’t segment by setting will blend these very different clinical environments into a single misleading average.
Site-of-service shifts compound the problem, and 2026 produced the largest example in a decade. Through 2025, most skin substitutes were paid under the ASP methodology, meaning the product’s own price drove reimbursement and created a strong incentive to apply high-cost grafts in the physician office. Effective January 1, 2026, CMS reclassified most skin substitutes as incident-to supplies paid at a single national rate of roughly $127 per square centimeter in both the physician office and the hospital outpatient department, eliminating that differential. Early reports describe office-based and mobile wound care providers scaling back or exiting CTP application in response. A manufacturer watching its volume decline in one setting while a competitor’s rises in another may be looking at a payment-driven relocation of care, not a loss of clinical share. Coverage language still matters where it exists: restrictions tied to wound type, application count, or documentation thresholds can concentrate a product’s real-world use in specific jurisdictions and settings regardless of how it performs elsewhere.
Analysts and market access teams who don’t segment utilization data by care setting risk drawing conclusions about “the CTP market” that are really conclusions about one segment of it, generalized past their evidentiary base. Setting-level breakdowns, the kind available through a registry-based dashboard tracking utilization across SNFs, home visits, and hospital-based wound centers, are what let you distinguish a genuine shift in clinical preference from a reimbursement-driven relocation of care.
Which Metrics Actually Define Utilization: Units, Episodes, or Square Centimeters?
“Utilization” gets used loosely, and the metric chosen changes the conclusion. Units billed under a HCPCS code is the most commonly cited figure because it’s the easiest to pull from claims data. For CTPs, that figure is less ambiguous than in most product categories: nearly every skin substitute Q-code is defined per square centimeter, so one unit is one cm² of product. The exceptions are the injectable and flowable products coded per cc or per milligram, which cannot be compared to sheet products on units at all. The real limitation of unit counts is subtler — units are square centimeters of product billed, which is not the same as square centimeters applied to a wound. Discarded portions of an opened graft were historically billable as wastage, and under the 2026 rules only the portion actually applied to the patient is payable. Unit totals that span that change are measuring two different things.
Two other framings do more useful work. Episodes of care, meaning the count of unique patients treated with a given product over a defined period, measures adoption breadth: how many clinicians and how many patients are being exposed to the product at all. Square centimeters per episode, or per application, measures treatment intensity: how much tissue a clinician commits once they have decided to use the product. A product can show strong episode counts (broad trial by many clinicians) alongside low cm² per episode (small wounds, conservative sizing, a single exploratory application), or the reverse — a smaller set of high-volume users applying large surface areas repeatedly. A raw national cm² total cannot distinguish those two pictures. The ratio between episodes and area can.
A common analytical error compounds this: treating raw claims volume trends as a direct proxy for clinical preference without adjusting for payment changes, coverage updates, or shifts in typical episode length. The 2026 reclassification is the clearest case — a payment change of that magnitude moves unit and dollar volume for nearly every product on the market for reasons that have nothing to do with clinical judgment. Coverage changes do the same at the jurisdiction level: the DFU and VLU LCDs scheduled to take effect January 1, 2026 would have limited coverage to 18 products, excluded 158, and left 154 to MAC discretion, and anyone who modeled 2026 volume around that framework was modeling a policy withdrawn a week before its effective date. Utilization figures that aren’t cross-checked against contemporaneous coverage and payment changes tend to overstate the role of clinical preference and understate the role of policy.
For manufacturers and HEOR teams, the practical takeaway is that no single metric is sufficient. Episodes treated, cm² applied per episode, and setting-segmented volume each answer a different question, and comparative effectiveness work that blends all three, ideally normalized against wound type and setting, produces a far more defensible read on where a product actually stands.
What Do Manufacturers and Analysts Get Wrong When Reading This Data?
The most persistent mistake is treating national claims totals as competitive market share. Regional MAC coverage policies concentrate CTP use geographically, sometimes sharply, and the current patchwork — three jurisdictions with active policies, four deciding case by case — makes that concentration more pronounced, not less. A product with a favorable coverage position in one jurisdiction can show strong national claims numbers that are really the sum of intense use in a handful of regions and near-absence elsewhere. Reading that as uniform national preference misreads what’s actually a coverage-policy artifact.
A second mistake is ignoring within-episode switching. Wound care episodes for DFUs and VLUs frequently involve more than one CTP applied sequentially as clinicians respond to healing trajectory, availability, or payer requirements. First-use data, the product applied at the start of an episode, tends to overstate that product’s role in eventual closure if a different product was applied in later, arguably more clinically decisive, applications. Utilization data that doesn’t track sequencing within an episode risks crediting or blaming the wrong product for an outcome.
A third mistake is conflating regulatory status or marketing enthusiasm with real-world adoption. It is worth being precise about what that status actually is: most CTPs on the market have never been cleared or approved by FDA. They are marketed as 361 HCT/Ps, a registration pathway with no premarket review of safety or effectiveness, and CMS’s 2026 rule sorts the field into exactly those three categories — 361 HCT/Ps, 510(k)-cleared devices, and PMA-approved devices. Regulatory status and launch messaging describe intended use and claims; they don’t describe what clinicians do once a product is on formulary. Utilization data frequently reveals a gap between launch-period enthusiasm and sustained use several quarters later, as clinicians settle into patterns based on outcomes, handling characteristics, reimbursement stability, and supply consistency rather than initial marketing claims. Manufacturers relying on launch-quarter sales figures as evidence of durable clinical preference are extrapolating from the least representative period in a product’s life cycle.
Each of these errors shares a root cause: substituting an available, easy-to-pull number (total claims, first-use counts, launch-quarter sales) for the harder, more specific analysis the question actually requires. Correcting for MAC-level geographic concentration, episode-level switching, and the launch-to-steady-state gap requires data granular enough to segment by region, sequence, and time, which is precisely what aggregate claims summaries are not built to do.
How Can This Data Be Used Defensively and Offensively?
Used defensively, CTP utilization data supports the evidentiary obligations manufacturers and providers increasingly face. The specific obligation depends on the pathway: post-market clinical follow-up is a standing requirement for manufacturers selling devices into the EU under MDR, US PMA products may carry post-approval study conditions, and 361 HCT/Ps carry no premarket evidence requirement at all — which is exactly why real-world utilization and outcomes data has become the practical currency with payers rather than a regulatory formality. Utilization patterns showing how a product is actually applied across settings and patient populations strengthen that record. The same data helps in payer audits and coverage appeals, where a documented pattern of appropriate, guideline-consistent use across a comparable population is more persuasive than a claims total alone. Documentation requests on CTP billing have escalated sharply — from MACs, from Unified Program Integrity Contractors, and through prior authorization under CMS’s WISeR model in participating states — and utilization data segmented by wound type, application frequency, and setting gives a factual basis for defending medical necessity that a bare claims count cannot provide.
Used offensively, the same data identifies where a product is under-penetrated relative to its clinical positioning: a region with low utilization despite favorable coverage, or a care setting where adoption lags a competitor with a similar indication profile. Comparative effectiveness studies and product ranking reports built on episode counts, cm² applied, and setting-adjusted outcomes let a manufacturer see where it stands against named competitors rather than against an unsegmented national average, and that ranking is what commercial and market access teams need to prioritize territory and account targeting.
The limitation worth stating plainly: no single dataset, claims-based or registry-based, captures the entirety of CTP use nationally. Claims data misses non-Medicare populations, bundled settings, and coding nuances; registry and wound care EHR data reflects the network of participating sites, not every wound center in the country. Cross-referencing claims data against registry and EHR sources, such as a dashboard tracking product utilization across SNFs, home visits, and hospital-based wound centers, narrows that gap considerably but does not eliminate it. Anyone presenting utilization figures as a complete national picture, from either source alone, is overstating certainty the underlying data doesn’t support.
CTP utilization data is only as reliable as its source and only as meaningful as the metric definitions behind it. A claims-derived unit count, a registry-derived episode count, and a cm²-normalized treatment-intensity figure can each tell a defensible story, but only if the reader knows which one they’re looking at and what it leaves out. The teams that get this right are the ones asking which metric answers their specific question, whether adoption breadth, treatment intensity, or geographic concentration, before pulling a number into a slide deck or a regulatory submission.
Intellicure Analytics’ Wound Care Industry Dashboard and Comparative Effectiveness Studies are built to give manufacturers, payers, and provider organizations setting-level, metric-adjusted utilization data rather than a single claims total presented as the whole story. Learn more about our services